Tags

Type your tag names separated by a space and hit enter

Efficacy of miltefosine for Bolivian cutaneous leishmaniasis.
Am J Trop Med Hyg. 2008 Feb; 78(2):210-1.AJ

Abstract

Oral miltefosine (2.5 mg/kg/d for 28 days) was compared with intramuscular antimony (20 mg/kg/d for 20 days) in the treatment of cutaneous leishmaniasis caused by Leishmania braziliensis in Palos Blancos, Bolivia. The cure rates with 6 months of follow-up were statistically similar: 36 of 41 evaluable miltefosine patients (88%) versus 15 of 16 (94%) evaluable antimony patients. However, antimony cured more rapidly, because, by 1 month after therapy, 31 of 44 miltefosine patients (70%) compared with 16 of 16 antimony patients (100%) had achieved cure. The two conclusions from this work are that oral miltefosine can be used for cutaneous disease in this part of Bolivia and that miltefosine was more effective for L. braziliensis in this region than for L. braziliensis in Guatemala. Chemotherapy needs to be evaluated in each endemic region, even if the "same" species of Leishmania causes disease in these locales.

Authors+Show Affiliations

Fundación FADER, Bogota, Colombia.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Randomized Controlled Trial

Language

eng

PubMed ID

18256415

Citation

Soto, Jaime, et al. "Efficacy of Miltefosine for Bolivian Cutaneous Leishmaniasis." The American Journal of Tropical Medicine and Hygiene, vol. 78, no. 2, 2008, pp. 210-1.
Soto J, Rea J, Balderrama M, et al. Efficacy of miltefosine for Bolivian cutaneous leishmaniasis. Am J Trop Med Hyg. 2008;78(2):210-1.
Soto, J., Rea, J., Balderrama, M., Toledo, J., Soto, P., Valda, L., & Berman, J. D. (2008). Efficacy of miltefosine for Bolivian cutaneous leishmaniasis. The American Journal of Tropical Medicine and Hygiene, 78(2), 210-1.
Soto J, et al. Efficacy of Miltefosine for Bolivian Cutaneous Leishmaniasis. Am J Trop Med Hyg. 2008;78(2):210-1. PubMed PMID: 18256415.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Efficacy of miltefosine for Bolivian cutaneous leishmaniasis. AU - Soto,Jaime, AU - Rea,Jaime, AU - Balderrama,Margarita, AU - Toledo,Julia, AU - Soto,Paula, AU - Valda,Luis, AU - Berman,Jonathan D, PY - 2008/2/8/pubmed PY - 2008/4/1/medline PY - 2008/2/8/entrez SP - 210 EP - 1 JF - The American journal of tropical medicine and hygiene JO - Am J Trop Med Hyg VL - 78 IS - 2 N2 - Oral miltefosine (2.5 mg/kg/d for 28 days) was compared with intramuscular antimony (20 mg/kg/d for 20 days) in the treatment of cutaneous leishmaniasis caused by Leishmania braziliensis in Palos Blancos, Bolivia. The cure rates with 6 months of follow-up were statistically similar: 36 of 41 evaluable miltefosine patients (88%) versus 15 of 16 (94%) evaluable antimony patients. However, antimony cured more rapidly, because, by 1 month after therapy, 31 of 44 miltefosine patients (70%) compared with 16 of 16 antimony patients (100%) had achieved cure. The two conclusions from this work are that oral miltefosine can be used for cutaneous disease in this part of Bolivia and that miltefosine was more effective for L. braziliensis in this region than for L. braziliensis in Guatemala. Chemotherapy needs to be evaluated in each endemic region, even if the "same" species of Leishmania causes disease in these locales. SN - 0002-9637 UR - https://www.unboundmedicine.com/medline/citation/18256415/Efficacy_of_miltefosine_for_Bolivian_cutaneous_leishmaniasis_ L2 - https://ClinicalTrials.gov/search/term=18256415 [PUBMED-IDS] DB - PRIME DP - Unbound Medicine ER -